Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs

American Journal of Managed Care

Volumn 2, Issue 2, 1996, Pages 139-143

  Streator, Scott E ^a,b   Shearer, Stephen W ^b  

^a Aetna Pharmacy Management ^*

^b AETNA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001001961     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA 1992;267:64-69.
2. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992;2:67-76.
3. Jaramilla JP. Migraine headaches: Characteristics and Treatment. Clin Trends Pharm Pract 1993;7:45-52.
4. Lipton RB, Stewart WF, Von Korff M. The burden of migraine. Pharmacoeconomics 1994;6:215-221.
5. Clouse JC, Osterhaus JT. Healthcare resource use and cost associated with migraine in a managed healthcare setting. Pharmacoeconomics 1994;May(28):659-664.
6. Solomon GD, Nielsen K, Miller D. The effects of sumatriptan (Imitrex) on migraine: Health-related quality of life. Med Interface 1995;June:134-141.
7. Diamond S. Diagnosis. In: Diagnosing and Managing Headaches,1st ed. Caddo, OK: Professional Communciatons;1994:23.
8. Abromowicz M, ed. Drugs for migraine. Med Lett 1995;37:17-20.
9. Cavallini A, Micieli G, Bussone G, et al. Headache and quality of life. Headache January 1995:29-35.